about
α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson diseaseGenome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffeePersonality characteristics and motor skills attributed to occupations in Parkinson diseaseClinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.QEEG Measures in Huntington's Disease: A Pilot Study.Replication of GWAS associations for GAK and MAPT in Parkinson's disease.Patients' and caregivers' experiences of the impact of Parkinson's disease on health statusRegional vulnerability in Huntington's disease: fMRI-guided molecular analysis in patients and a mouse model of disease.Vitamin D receptor gene polymorphisms and Parkinson's disease in a population with high ultraviolet radiation exposure.Marked amelioration of alcohol-responsive posthypoxic myoclonus by gamma-hydroxybutyric acid (Xyrem).A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders.Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease.Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study.PET imaging of neuropathology in tauopathies: progressive supranuclear palsyAssociations of sleep disturbance symptoms with health-related quality of life in Parkinson's diseaseParkinson's disease is associated with DNA methylation levels in human blood and saliva.Organophosphate pesticides and PON1 L55M in Parkinson's disease progression.Vitamin D receptor gene polymorphisms and cognitive decline in Parkinson's disease.Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?The Role of Stress as a Risk Factor for Progressive Supranuclear Palsy.APOE, MAPT, and COMT and Parkinson's Disease Susceptibility and Cognitive Symptom Progression.A pilot efficacy and tolerability trial of memantine for essential tremor.Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications.Atypical parkinsonian disorders. Preface.Diffusion tractography imaging-guided frameless linear accelerator stereotactic radiosurgical thalamotomy for tremor: case report.Primary angiitis of the CNS (PACNS) with predominant cranial neuropathy and spinal cord involvement.Anti-inflammatory drug use and progressive supranuclear palsy.Pallidal deep brain stimulation modulates excessive cortical high β phase amplitude coupling in Parkinson disease.Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study.Pallidal stimulation in Parkinson disease differentially modulates local and network β activityClinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis.
P50
Q21090919-B3249A8D-04D1-4B07-A377-5DD429033046Q21092426-076ED95F-737D-4753-A0F9-09BF092C1752Q28383080-4CBC1C71-3DC4-492B-8BF3-E7CD484A0CEEQ30278084-DFD12392-60F0-4FFF-B313-1A70F276FD8EQ33734662-493FB0DE-7BA1-47A0-B26E-4FACDB6C8D36Q34781481-B0ED2478-0D28-48F9-888F-0B71737D5614Q35052613-B13F4CAA-255D-4B6C-B996-4C3510D6F3CCQ35619936-71BB20E9-71D8-48F3-B591-20A39EDD48C4Q35772154-B03F94D4-3A2A-4E49-894F-E27C9F43CBD7Q36063468-C1EEE336-F74B-4A94-9969-E01EBF3BE901Q36178486-D9E86AB7-AF58-47E3-B3AC-82141F137753Q36439181-2ED35726-399C-45E5-88C1-0B606F7C43BCQ36885365-80F3E5F9-F888-4E6D-A1C3-2FF83EAE8F0AQ36906654-AD71C988-F123-4DF0-B786-7C125A505852Q37651800-4180FD02-BB9E-4FAA-BEA2-69DBEF49E66FQ38603331-1D80AE47-5BFC-4E68-BA78-118FF743032CQ38660920-A155DA70-51FC-4CD7-A30F-3ECD09342205Q38807003-884D7687-5218-41A2-983F-6DA2A5E171DAQ38807324-5F5D8B80-DD7C-4D18-8D27-216FB22039F4Q39303669-CA0EC73C-C1AD-4419-B989-C9EBAA215A24Q40242476-77559A0A-82AA-4CD4-9432-0204D57C4B4FQ40809659-F7DC0CBF-F26B-47BA-B1A2-45601B230B0EQ42675076-41438B18-18D4-4531-81BA-DB370D798BD6Q45305061-79011ECC-8EF3-4907-A84A-DF7067670DC0Q45962439-0E1710C7-8B97-4FAB-8BE8-A19B974B5024Q46031341-7B3D8FC7-0708-425E-AE70-CEA04996D1CDQ46037348-8D6FA9B4-144E-47BB-8F6D-03C13EC4269AQ47200822-970261A2-5574-4190-A086-60CA67F067E0Q48499171-F0A40306-2B03-44F6-92A9-D9F86796B655Q49817768-93329D04-3652-4643-9BBD-D8FB6C94D5F7Q57987791-CE4025F6-2294-4853-88DB-483AAB30FC88Q64976067-996028A2-8FB7-40F0-836B-8B7D9BFBC221
P50
name
Yvette Bordelon
@ast
Yvette Bordelon
@en
Yvette Bordelon
@nl
type
label
Yvette Bordelon
@ast
Yvette Bordelon
@en
Yvette Bordelon
@nl
altLabel
Bordelon Y
@en
Bordelon Y.
@en
Bordelon
@en
Y Bordelon
@en
Y. Bordelon
@en
prefLabel
Yvette Bordelon
@ast
Yvette Bordelon
@en
Yvette Bordelon
@nl